Drug discovery and development

You may not know that as well as funding cancer research, we also work with industry and academia to develop promising ideas and turn them into real benefit for patients. Find out about Cancer Research Horizons.

Sacituzumab govitecan (Trodelvy) is not being recommended by NICE for use in England as a treatment for some people with triple-negative breast cancer.

Forty years ago, hints of a new component of the immune system caused a stir. Here, we chart the story of gamma delta T cells from discovery to clinical trials…

“Our motivation for studying it is because there haven’t been any new effective treatments for decades.” Overall, survival for children’s…

To mark 20 years since the merger of the Cancer Research Campaign and the Imperial Cancer Research Fund, we’ve delved into the research of the charities’ that led to many of the drugs in use today.

Pioneering therapeutics targeting the damage repair mechanism of DNA polymerase theta in a range of cancers have entered human trials – we tell the story from discovery to translation.

From groundbreaking rare cancer research to ending up on Forbes 30 under 30, we chat to Sigourney Bell about her work in the lab and her global organisation, Black in Cancer.

Dr Lisa Ruff tells us why drug delivery is so important for the treatment of paediatric brain tumours – and why hydrogels could be key to a breakthrough…

Find out how the chemistry inside plants can lead to life-changing drugs and how a cannabis-derived drug is part of a new trial to help people with a type of aggressive brain cancer.

The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year.